

MYELOFIBROSIS 2022 – “Face the future by challenging the past”
– 3rd ed.
Forlì, November 17-18,2022

Evento residenziale accreditato ECM nazionale-CME

Accreditamento per 100 persone

Responsabile scientifico: Dr. Alessandro Lucchesi

Sede: tbd

RATIONALE

Myelofibrosis (MF) is experiencing a lively moment from a scientific point of view. As hypothesized in previous editions of the meeting, JAK2 inhibitors retain a backbone role in newer and promising therapeutic combinations that could undermine the pathogenic basis of MF. Biological data collected in clinical trials highlight the possibility of modulating some important features that drive disease aggressiveness, such as fibrosis, allelic burden of mutations, proinflammatory cytokines, and the microenvironment. The result is an overall improvement in clinical outcomes, which the scientific community is watching with increasing interest. This year's congress aims to devise the best strategies for MF patients starting from their preclinical rationale.

PROGRAMME

THURSDAY NOVEMBER 17th, 2022

15:00-15:15 Welcome & introduction (G. Martinelli)

15:15 – 16:30 The maze: Immunological aspects of myelofibrosis (Chair: C. Fava, G. Musuraca)

15:15 – 15:35 Immunological dysregulations in MPNs: an overview (G. Giordano)

15:40 – 16:00 Rheumatological diseases and MPNs: common aspects, shared solutions (S. Galimberti)

16:05 – 16:25 Targets and approaches for immunotherapy in MPNs (M. Holmstrom)

16:30 – 16:55 Lecture (Chair: S. Galimberti)

Recent advances on the correlation between genetic and clinical aspects in myelofibrosis (R. Manfredini)

16:55 – 17:10 coffee break

17:10 – 18:20 The storm: Inflammation and Thrombosis (Chairs: L. Catani, M.T. Bochicchio)

17:10 – 17:30 Platelet heterogeneity in MPNs (A. Krishnan)

17:35 – 17:55 Inflammasomes and thrombo-inflammation in MPNs (A. Lucchesi)

18:00 – 18:20 MPNs and unusual site thrombosis (M. Napolitano)

18:20 – 18:30 Day 1 conclusions (B. Mora, A. Lucchesi)

FRIDAY NOVEMBER 18th, 2022

09:30 – 09:45 Welcome and Introduction (B. Mora, A. Lucchesi)

09:45 – 11:10 Educational Symposium (Chair: G. Rosti, M. Poggiaspalla)

09:45 – 10:10 Stratifying to improve decision-making: evolution of prognostic scores (B. Mora)

10:15 – 10:40 Current status and perspectives for bone marrow transplant in myelofibrosis (A. Olivieri)

10:45 – 11:10 Impact, prophylaxis and management tips of SARS-CoV-2 infection in patients with MPN and CML (M. Breccia)

11:10 – 11:25 coffee break

11:25 – 12:50 Clinical session 1: Prognosis and JAK inhibition (Chair: M. Breccia, D. Cilloni)

11:25 – 11:55 Old-fashioned cytoreductive drugs and anti-anaemic agents: to be saved or to be forgotten? (G. Micucci)

12:00 – 12:20 Ruxolitinib: a long history, yet to be written (F. Palandri)

12:25 – 12:50 Lecture: New JAK inhibitors: is there room for them all? (C. Harrison)

12:50 – 14:20 light lunch

14:20 – 15:35 Clinical Session 2: New targets in the spotlight (Chairs: G. Musuraca, J. Mascarenhas)

14:20 – 14:40 BET inhibitors and other epigenetic modifiers in MF (A. Patriarca)

14:45 – 15:05 Inflammasome and microenvironment targeted therapies (D. Cilloni)

15:10 – 15:30 Apoptosis inducers and anti-proliferative drugs (J. Mascarenhas)

15:35 – 15:55 Multi-target agents: XPO1 and AURK inhibitors (S. Tantravahi)

16:00 - 16:40 Perspectives (Chair: B. Mora, A. Lucchesi, A. Patriarca)

Round table: Selection of the most promising translational experiences (D. Cilloni, G. Giordano)

Round table: "Novelties and priorities: how will future guidelines change?" (J. Mascarenhas, C. Harrison)

16:45 – 16: 50 Conclusions: Dr. G. Rosti, Dr. A. Lucchesi

NON ACCREDITATO ECM

FRIDAY NOVEMBER 18th, 2022

16:50 – 17:00 Accoglienza pazienti

1st MPN PATIENTS' DAY

Moderatori: G. Musuraca, P. Tosi, F. Lanza, M.T. Montella

17:00 – 17:30 Ricordo del Presidente Gaetano Foggetti: R. Camporesi, P. Cupo, G. Musuraca

17:30 – 18:00 Inquadramento della malattia, strumenti diagnostici e prognostici (*G. Giordano, B. Mora*)

18:00 – 18:30 Prevenzione e profilassi del rischio trombotico (G. Micucci, M. Napolitano)

18:30 – 19:00 Terapie convenzionali vs nuove terapie in trial clinico (A. Lucchesi, M. Poggiaspalla)

19:00 – 19:10 Conclusions